Family of vCJD victim claim untried treatment is success
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The family of a teenage boy dying from variant Creutzfeldt-Jakob disease who defied medical advice to give him an experimental drug claims that the treatment is beginning to work.
The family of a teenage boy dying from variant Creutzfeldt-Jakob disease who defied medical advice to give him an experimental drug claims that the treatment is beginning to work.
Don Simms, whose son Jonathan was given a year to live, said that since starting the treatment involving injections directly into the brain there were signs that the disease, linked with eating BSE-infected meat, had been brought under control.
"We see that he is more responsive. It is a suggestion that the treatment is working," he says on the BBC 1 programme Real Story, to be broadcast tonight.
In December 2002, the Simms family won a High Court ruling to allow the untried treatment to go ahead, despite warnings of the dangers from specialists. The Committee on Safety of Medicines said there was "no rational basis" for prescribing the drug and the CJD Therapy Advisory Group said there was insufficient data on its effect and safety.
After hearings in London and Belfast, Dame Elizabeth Butler-Sloss decided the risk was acceptable because without treatment Jonathan would die.
Surgeons placed an ommaya reservoir, a plastic dome-like device, under his scalp with a tube leading into the brain. The drug pentosan polysulphate was put in the reservoir and infused slowly. The drug had not been used to treat vCJD before, although it had slowed the disease's progress in animals.
The case set a legal precedent for the use of experimental treatments on people with a terminal illness who are incapable of giving consent, and opened the way for other patients with vCJD to seek the same treatment.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments